Toleranzia

Toleranzia is in a very intensive phase of operations with several ongoing clinical trial preparatory activities prior to the start of the clinical phase I/IIa study of the drug candidate TOL2 for the treatment of myasthenia gravis. In order to complete the remaining preparations, a capital injection into the Company will be required shortly. Furthermore, as a clinical trial should not be initiated before full funding is secured, additional – and not insignificant – capital injections will be needed.

The Board has evaluated several possible financing alternatives and concluded that, in the current market conditions, it is challenging to raise capital in a listed environment. There is therefore a significant risk that the necessary capital cannot be obtained. This would have negative consequences for the Company's development work, financial results and financial position and ultimately affect the Company's market value negatively.

As previously announced, Toleranzia has received a merger offer from Flerie AB and the Board of Directors has, in light of the above, unanimously recommended the shareholders of Toleranzia to vote in favor of a merger with Flerie AB in accordance with the offer presented. If the offer is rejected, there is considerable uncertainty regarding Toleranzia's ability to continue as a going concern, which may have serious consequences for the Company's future development.

The conditional loan agreement was signed on market terms and runs without collateral. The interest rate amounts to a maximum of SEK nine hundred and ninety thousand.

"Toleranzia will shortly need external financing to continue its operations. The credit facility serves as a crucial enabler to complete the remaining clinical trial preparations, while also providing valuable time to secure full funding for the clinical trial of TOL2. In addition to the capital injection, we are very pleased with the confidence shown in us by our main shareholder, which adds significant strength and stability to the company's operations", comments Charlotte Fribert, CEO of Toleranzia.

For further information, please contact
Charlotte Fribert - CEO, Toleranzia AB
Tel: +46 763 19 98 98
E-post: charlotte.fribert@toleranzia.com

About Toleranzia AB (publ)
Toleranzia AB (publ) develops medicines that harness the power of the immune system to treat rare autoimmune diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, just reduce symptoms. They have the potential to be the first long-acting or curative treatments that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on Nasdaq First North Growth Market and Svensk Kapitalmarknadsgranskning AB, +46 (0)8 913 008, ca@skmg.se, is the company's Certified Adviser.